4.6 Review

Surveillance of Antigen-Presenting Cells by CD4+CD25+Regulatory T Cells in Autoimmunity Immunopathogenesis and Therapeutic Implications

Journal

AMERICAN JOURNAL OF PATHOLOGY
Volume 174, Issue 5, Pages 1575-1587

Publisher

ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2009.080987

Keywords

-

Categories

Funding

  1. Institut National de la Sante et de la Recherche Medicale (INSERM)
  2. Centre National de la Recherche Scientifique (CNRS)
  3. UPMC-Paris VI
  4. Agence Nationale de la Recherche [ANR-07-JCJC-0100-01, ANR-07-RIB-002-02]

Ask authors/readers for more resources

CD4+CD25+ regulatory T cells (Tregs) play a critical role in preventing immune aggression. One way in which Tregs exert immune surveillance activities is by modifying the function of antigen presenting cells (APCs) such as dendritic cells, macrophages, and B cells. Tregs can induce apoptosis of APCs or inhibit their activation and function, thereby regulating subsequent innate and adaptive immune responses. These actions of Tregs are mediated by both soluble factors (interleukin [IL]-10, transforming growth factor-beta, perforins, granzymes) and cell-associated molecules (cytotoxic T lymphocyte antigen 4, lymphocyte activation gene-3, CD18, neuropilin-1, LFA-1/CD11a, CD39), of which cytotoxic T lymphocyte antigen 4 has a key role. However, in autoimmunity, chronically activated APCs under the influence of intracellular signaling pathways, such as phosphatidyl inositol 3 kinase, JAK-STAT, MAPK, and nuclear factor-kappa B pathways, can escape surveillance by Tregs, leading to the activation of T cells that are refractory to suppression by Tregs. Moreover, APCs and APC-derived inflammatory cytokines such as tumor necrosis factor, IL-6, IL-10, and IL-23 can render Tregs defective and can also reciprocally enhance the activity of the IL-17-producing pathogenic Th17 T cell subset. Emerging knowledge of the importance of APC-Treg interactions in maintaining immune tolerance and aberrations in this cross talk in autoimmune diseases provides a rationale for therapeutic approaches specifically targeting this axis of the immune system. (Am J Pathol 2009, 174:1575-1587; DOI: 10.2353/ajpath.2009.080987)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available